Skip to content

The Clinical trials of Vagus Nerve Stimulation

The Clinical trials of Vagus Nerve Stimulation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100047742
Enrollment
Unknown
Registered
2021-06-26
Start date
2016-03-09
Completion date
Unknown
Last updated
2022-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intractable epilepsy

Interventions

Sponsors

Xuanwu Hospital Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Aged 6 to 45 years; 2. Those with good compliance and could complete postoperative follow-up; 3. Those who did not participate in other clinical trials within three months; 4. Generalized or multifocal epilepsy, or no definite localized epileptogenic focus; 5. Those who have seizures more than 3 times (including 3 times) in 3 months and have seizures more than once per month; 6. Under the guidance of neurologist,those were treated with regular antiepileptic drugs, but failed to effectively control the seizure, and were diagnosed as drug refractory epilepsy (patients who could not be completely controlled by drugs and were not suitable for craniotomy); 7. Those who voluntarily participate in the trial and sign a written informed consent.

Exclusion criteria

Exclusion criteria: 1. Those who refuse to participate in the trial or sign written informed consent; 2. Women in lactation, pregnancy or preparation for pregnancy; 3. Those with a history of vagotomy in the left neck; 4. Those with progressive neurological or systemic diseases; 5. Patients with arrhythmia, asthma or active lung disease and peptic ulcer; 6. Patients with insulin-dependent diabetes; 7. Patients with sleep apnea syndrome; 8. Patients who are undergoing or are expected to receive strong electromagnetic treatment or examination in the observation period; 9. Patients who have participated in other clinical trials within three months; 10. Other situations that researchers and medical staff think are not suitable for selection.

Design outcomes

Primary

MeasureTime frame
Effectiveness, >=50%seizure reduction;Safety evaluation;

Countries

China

Contacts

Public ContactYuping Wang

Xuanwu Hospital Capital Medical University

wangyuping01@sina.cn+86 10 83198277

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026